J. Hernandez, S. Miguel, and J. , High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma, British Journal of Haematology, vol.107, pp.121-131, 1999.

K. Anderson, R. Kyle, S. Rajkumar, A. Stewart, D. Weber et al., Clinically relevant end points and new drug approvals for myeloma, Leukemia, vol.88, issue.2, pp.231-239, 2008.
DOI : 10.1182/blood-2006-04-015909

S. Minvielle, J. Harousseau, T. Facon, and C. Mathiot, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome, Blood, vol.109, pp.3489-3495, 2007.

W. Kuehl, J. Shaughnessy, and G. Tricot, Advances in biology and therapy of multiple myeloma, 2003.

R. Bataille, G. Jego, N. Robillard, S. Barille-nion, J. Harousseau et al., The phenotype of normal, reactive and malignant plasma cells, 2006.

R. Bataille, C. Pellat-deceunynck, N. Robillard, H. Avet-loiseau, J. Harousseau et al., CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis, Leukemia Research, vol.32, issue.3, pp.379-382, 2008.
DOI : 10.1016/j.leukres.2007.07.016

C. Binet, J. Domenech, and O. Herault, Cellules souches hématopoïétiques : propriétés, description des différents types, schéma de l'hématopoïèse, 2004.

M. Colovic, G. Jankovic, N. Suvajdzic, N. Milic, V. Dordevic et al., Thirty patients with primary plasma cell leukemia: a single center experience, Medical Oncology, vol.19, issue.2, pp.154-160, 2008.
DOI : 10.1056/NEJM198405243102104

J. Gastaut, D. Olive, P. Rousselot, and P. Chaibi, Primary plasma cell leukaemia: a report of 18 cases, Leukemia Research, vol.25, pp.103-107, 2001.

F. Davies, A. Rawstron, R. Owen, and G. Morgan, Minimal residual disease monitoring in mutliple myeloma. Best Practice and Research, Clinical Haematology, vol.15, pp.197-222, 2002.

D. Tute, R. Jack, A. Child, J. Morgan, G. Owen et al., A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma, Leukemia, vol.121, issue.9, 2007.
DOI : 10.1046/j.1365-2141.2001.02530.x

F. Dignat-georges, N. Bardin, and C. Brunet, Lymphocytes et réponse immunitaire, 2006.

A. Dispenzieri, R. Kyle, G. Merlini, J. Miguel, H. Ludwig et al., International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, on behalf of the International Myeloma Working Group, pp.215-224, 2009.
DOI : 10.1038/leu.2008.307

B. Durie and S. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.126, issue.3, pp.842-854, 1975.
DOI : 10.3181/00379727-125-32327

M. Boccadoro, I. Turesson, J. D. Vesole, D. Kyle, R. Alexanian et al., International uniform response criteria for multiple myeloma, on behalf of the International Myeloma Working Group, pp.1467-1473, 2006.

S. Ely and D. Knowles, Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation, The American Journal of Pathology, vol.160, issue.4, pp.1293-1299, 2002.
DOI : 10.1016/S0002-9440(10)62556-4

X. Jouet, J. Bauters, F. Harousseau, J. Bataille, R. Mary et al., Chromosome 13 abnormalities identified by FISH analysis and serum {beta}2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, vol.97, pp.1566-1571, 2001.

Y. Frenandez, T. Miller, C. Denoyelle, J. Esteban, W. Tang et al., Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib, Journal of Biological Chemistry, vol.127, issue.2, pp.1107-1118, 2006.
DOI : 10.1182/blood-2002-08-2543

J. Ashcroft, G. Cook, and R. Owen, IgM myeloma: a rare entity, 2008.

A. Stewart and H. Avet-loiseau, Genetics and cytogenetics of multiple myeloma: a workshop report, Cancer Research, vol.64, pp.1546-1558, 2004.

R. Garand, H. Avet-loiseau, F. Accard, P. Moreau, J. Harousseau et al., t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma, Leukemia, vol.101, issue.10, pp.2032-2035, 2003.
DOI : 10.1182/blood-2002-08-2436

J. Perez-simon, A. Rasillo, S. Miguel, and J. , Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics, Blood, vol.93, pp.1032-1037, 1999.

J. Gardais, F. Genevieve, C. Foussard, V. Delisle, and M. Zandecki, Is there any significance for intracellular crystals in plasma cells from patients with monoclonal gammopathies?, European Journal of Haematology, vol.13, issue.2, pp.119-122, 2001.
DOI : 10.1097/00005792-200005000-00002

M. Monconduit, J. Michaux, and T. Facon, Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology, Leukemia Research, vol.23, pp.1133-1140, 1999.

B. Van-ness and R. Kyle, Plasmablastic morphology. An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group, Blood, vol.91, pp.2501-2507, 1998.

C. Shutsik, P. Sonneveld, P. Tosi, I. Turesson, and J. Westin, International Staging System for multiple myeloma, Journal of Clinical Oncology, vol.23, pp.3412-3420, 2005.

J. Harousseau, J. Shaughnessy, and P. Richardson, Multiple Myeloma, Hematology, vol.2004, issue.1, pp.237-256, 2004.
DOI : 10.1182/asheducation-2004.1.237

URL : https://hal.archives-ouvertes.fr/inserm-00479729

C. Hulin, Mise au point. Les nouveaux médicaments du myélome. La Revue de médecine interne, pp.682-688, 2007.

N. Evans, M. Chappell, M. Cook, H. Goehl, M. Storr et al., Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies, 2007.

P. Richardson, V. Tornout, J. Zhao, C. Singhal, A. Anderson et al., Phase ½ study of elotuzumab in combination with bortezomib in patients with multiple myeloma following 1 to 3 prior therapies: interim results, 2009.

C. Pellat-deceunynck, Reactive plasmocytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, vol.94, pp.701-712, 1999.

M. Johnson, D. Carpio-jayo, D. Lin, P. Giralt, S. Anderlini et al., Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation, Annals of Diagnostic Pathology, vol.10, issue.5, pp.263-268, 2006.
DOI : 10.1016/j.anndiagpath.2005.12.011

M. Jourdan, A. Caraux, D. Vos, J. Fiol, G. Larroque et al., An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization, Blood, vol.114, issue.25, pp.5173-5181, 2009.
DOI : 10.1182/blood-2009-07-235960

URL : https://hal.archives-ouvertes.fr/inserm-00446133

J. Offord, D. Larson, M. Plevak, T. Therneau, and P. Greipp, Review of 1027 patients with newly diagnosed multiple myeloma, pp.21-33, 2003.

R. Kyle and S. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, vol.22, issue.1, pp.3-9, 2009.
DOI : 10.1038/leu.2008.291

T. Lebien, Fates of human B-cell precursors, Blood, vol.96, pp.9-23, 2000.

T. Lebien and T. Tedder, B lymphocytes: how they develop and function, 46. Lees O & Béné MC et les membres du GEIL, pp.1570-1580, 1998.
DOI : 10.1182/blood-2008-02-078071

P. Lin, R. Owens, G. Tricot, and C. Wilson, Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma, American Journal of Clinical Pathology, vol.121, issue.4, pp.482-488, 2004.
DOI : 10.1309/74R4TB90BUWH27JX

J. Lopez, O. Dauwalder, P. Joly, I. Dimet, J. Bienvenu et al., Intérêt et limites des dosages sériques et urinaires des chaînes légères libres pour le diagnostic et le suivi des dysglobulinémies monoclonales, Annales de Biologie Clinique, vol.64, pp.287-297, 2006.

P. Lydyard, A. Whelan, and M. Fanger, L'essentiel en immunologie, 2002.

J. Mediavilla, A. Pandiella, J. Lahuerta, A. Orfao, S. Miguel et al., Genetic abnormalities and patterns of antigenic expression in multiple myeloma, Clinical Cancer Research, vol.11, pp.3661-3667, 2005.

J. Ojanguren, F. De-arriba, L. Palomera, M. Terol, A. Orfao et al., Pronostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression, Journal of Clinical Oncology Blood, vol.26, issue.99, pp.2737-27442154, 2002.

J. Bataille and R. , Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma, Haematologica, vol.89, issue.56, pp.547-551, 2004.

J. Harousseau and R. Bataille, Lack of CD27 in myeloma delineates different presentation and outcome, British Journal of Haematology, vol.132, pp.168-170, 2005.

F. Garnache, R. Garand, N. Varoqueaux, H. Avet-loiseau, J. Harousseau et al., Rituximab in CD20 positive multiple myeloma, Leukemia, vol.21, pp.835-836, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00479729

A. Greipp, P. Kyle, R. Rajkumar, V. Ocqueteau, M. Orfao et al., Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma, Blood, vol.106, issue.60, pp.2276-2279, 2005.

R. Owen and A. Rawstron, Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice, British Journal of Haematology, vol.99, issue.1, pp.732-733, 2005.
DOI : 10.1182/blood-2003-01-0189

A. Martin, J. Blade, J. Lahuerta, A. Orfao, S. Miguel et al., Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, pp.4017-4023, 2008.

J. Orfao, A. , S. Miguel, and J. , Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients, Haematologica, vol.94, pp.1599-1602, 2009.

M. Berges, S. Miguel, J. Orfao, and A. , Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Clinical Cytometry, vol.78, pp.239-252, 2010.

C. Pellat-deceunynck, R. Bataille, N. Robillard, J. Harousseau, M. Rapp et al., Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells, Blood, vol.84, pp.2597-2603, 1994.

C. Pellat-deceunynck, S. Barille, D. Puthier, M. Rapp, J. Harousseau et al., Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization, Cancer Research, vol.55, pp.3647-3653, 1995.
URL : https://hal.archives-ouvertes.fr/hal-01595839

J. Harousseau, M. Amiot, and R. Bataille, The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukaemia and of a special subset of multiple myeloma, Leukemia, vol.12, pp.1977-1982, 1998.

C. Pellat-deceunynck and R. Bataille, Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression, Blood Cells, Molecules, and Diseases, vol.32, issue.2, pp.293-301, 2004.
DOI : 10.1016/j.bcmd.2003.12.001

J. Orfao and A. , Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment, Leukemia, vol.19, pp.449-455, 2005.

J. Galende, R. Cuello, I. Abuin, I. Moreno, M. Dominguez et al., Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease, International Journal of Cancer, vol.124, pp.367-375, 2009.

J. Galende, G. Martin-nunez, J. Alonso, N. De-las-heras, J. Hernandez et al., New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, Blood, vol.110, pp.2586-2592, 2007.

K. Raja, L. Kovarova, and R. Hajek, Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, British Journal of Haematology, vol.8, issue.3, pp.334-351, 2010.
DOI : 10.1093/ajcp/75.1.1

A. Jack, J. Child, and G. Morgan, Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation, Blood, vol.100, pp.3095-3100, 2002.

R. Owen, CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy, Haematologica, vol.91, pp.1577-1578, 2006.

M. Rapp, J. Harousseau, M. Amiot, and R. Bataille, CD28, a marker associated with tumoral expansion in multiple myeloma, Clinical Cancer Research, vol.4, pp.1521-1526, 1998.
URL : https://hal.archives-ouvertes.fr/hal-01595835

R. Bataille, CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma, Blood, vol.102, pp.1070-1071, 2003.

N. Robillard, C. Pellat-deceunynck, and R. Bataille, Phenotypic characterization of the human myeloma cell growth fraction, Blood, vol.105, issue.12, pp.4845-4848, 2005.
DOI : 10.1182/blood-2004-12-4700

G. Roodman, Pathogenesis of myeloma bone disease, Leukemia, vol.139, issue.3, pp.435-441, 2009.
DOI : 10.1532/IJH97.07030

N. Sahara, M. Ihara, T. Ono, S. Tamashima, H. Matsui et al., Multiple myeloma expressing CD19+CD56? phenotype, American Journal of Hematology, vol.82, issue.4, pp.311-313, 2000.
DOI : 10.1002/1096-8652(200008)64:4<311::AID-AJH13>3.0.CO;2-U

URL : http://onlinelibrary.wiley.com/doi/10.1002/1096-8652(200008)64:4<311::AID-AJH13>3.0.CO;2-U/pdf

S. Yamashima, K. Nara, K. Ohnishi, and R. Ohno, Clinicopathological and prognostic characteristics of CD56-negative mutliple myeloma, British Journal of Haematology, vol.117, pp.882-885, 2002.

M. Moro, J. Fernandez-calvo, J. Diaz-mediavilla, L. Palomera, and A. Orfao, Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome, Blood, vol.99, pp.1853-1856, 2002.

S. Miguel, J. Gutierrez, N. Mateo, G. Orfao, and A. , Conventional diagnostics in multiple myeloma, European Journal of Cancer, vol.42, issue.11, pp.1510-1519, 2006.
DOI : 10.1016/j.ejca.2005.11.039

J. Hernandez, J. Lahuerta, A. Orfao, M. Gonzalez, S. Miguel et al., Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry, Haematologica, vol.90, pp.1365-1372, 2005.

M. Shapiro-shelef and K. Calame, Regulation of plasma-cell developpement, Nature Reviews Immunology, vol.5, pp.231-242, 2005.

L. Kumar, S. Greipp, P. Clark, R. Rajkumar, and S. , Pronostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system, 2008.

S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC. 92, 2008.

T. Grogan, Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19), Blood, vol.76, pp.377-382, 1990.

S. Minvielle, H. Avet-loiseau, and . For-the-intergroupe-francophone-du-myélome, Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, 2005.